BibTex RIS Kaynak Göster

Kemerin

Yıl 2015, Cilt: 4 Sayı: 3, 468 - 481, 01.07.2015

Öz

Modern hayat tarzı, teknolojiye paralel olarak değişen yemek alışkanlıkları ve her geçen gün daha sık maruz kalınan stres koşulları aşırı kilo artışı, insülin rezistansı, hipertansiyon,Tip 2 diyabet gibi hastalıklara yakalanma riskini arttırmaktadır. Adipoz doku yağ depolama görevi yanında birçok hastalıkla ilişkili olduğu bilinen adipokinlerin sentez ve salgılanmasından sorumlu endokrin bir organdır. Yakın zamanda adipoz dokudan salınan bir adipokin çeşidi olduğu tespit edilen kemerin başta kemoatraktant fonksiyonu olmak üzere; adipogenezis, anjiogenezis ve glukoz homeostazı gibi birçok metabolik olayla ilişki bir proteindir. Adipoz dokudan inaktif formda salınan kemerin aktif olduğu fonksiyonel formlarına çeşitli proteazlarla karboksil terminalindeki aminoasitlerin uzaklaştırılmasıyla dönüşebilir. Kemerin seviyesinin inflamasyon, diyabet, metabolik sendrom, kardiyovasküler hastalıklı bireylerde sağlıklı kişilere göre daha yüksek olması gelecekte bu hastalıkların ön belirteci olarak teşhis ve kontrolünde yeni bir teröpatik yaklaşım sağlayabileceği savunulmaktadır.
Bu derlemenin amacı farklı metabolik yollarda önemli düzenleyici roller üstlenen kemerinin yapısı, görevleri ve hastalıklarla ilişkisinden bahsetmektir.

Kaynakça

  • Bays HE. Adiposopathy Is “Sick Fat” A Cardiovascular Disease? J Am Coll Cardiol 2011; 57: 2461–73.
  • Li Y, Shi B, Li S. Association Between Serum Chemerin Concentrations And Clinical Indices In Obesity Or Metabolic Syndrome: A Meta-Analysis. PLoS ONE 2014; 9; (12): e113915.
  • Altunkaynak BZB, Özbek E. Yağ Dokusu Endokrin Bir Organ Mıdır? Dicle Tıp Dergisi 2005; 32: 211-7.
  • Karastergiou K, Mohamed-Ali V. The Autocrine And Paracrine Roles Of Adipokines. Mol Cell Endocrinol 2010; 318: 69–78.
  • Rokling-Andersen MH, Reseland JE, Veierød MB, Anderssen SA, Jacobs Jr DR, Urdal P, Jansson JO, Drevon CA. Effects Of Long-Term Exercise And Diet Intervention On Plasma Adipokine Concentrations. Am J Clin Nutr 2007; 86: 1293–301.
  • Takeishi Y. Resistin Is A Novel Biomarker For A Risk Of Heart Failure. J Cardiovasc Dis Diagn 2013; 1:4.
  • AL-Suhaimi EA, Shehzad A. Leptin, Resistin And Visfatin: The Missing Link Between Endocrine Metabolic Disorders And Immunity. European Journal of Medical Research 2013; 18:12.
  • Crandall DL, Quinet EM, Morgan GA, Busler DE, Mchendry-Rinde B, Kral JG. Synthesis And Secretion Of Plasminogen Activator Inhibitor-1 By Human Preadipocytes. J Clin Endocrinol Metab 1999; 84: 3222–3227.
  • Berg AH, Scherer PE. Adipose Tissue, Inflammation, And Cardiovascular Disease. Circ Res 2005; 96: 939-949.
  • Alessi MC, Juhan-Vague I. PAI-1 And The Metabolic Syndrome Links, Causes, And Consequences. Arterioscler Thromb Vasc Biol 2006; 26: 2200-2207.
  • Ernst MC, Sinal CJ. Chemerin: At The Crossroads Of Inflammation And Obesity. Trends in Endocrinology and Metabolism 2010; 21:11.
  • Oberbach A, Kirscha K, Lehmanna S, Schlichting N, Fasshauer M, Zarse K, Stumvoll M, Ristow M, Blüher M, Kovacs P. Serum Vaspin Concentrations Are Decreased After Exercise-Induced Oxidative Stress. Obes Facts 2010; 3: 328–331.
  • Tiaka EK, Manolakis AC, Kapsoritakis AN, Potamianos SP. The Implication Of Adiponectin And Resistin In Gastrointestinal Diseases. Cytokine & Growth Factor Reviews 2011; 22: 109–119.
  • Bohler H, Mokshagundam S, Winters SJ. Adipose Tissue And Reproduction In Women. Fertil Steril 2010; 94: 795–825.
  • Fain JN. Release Of Inflammatorymediators By Human Adipose Tissue Is Enhanced In Obesity And Primarily By The Nonfat Cells: A Review. Mediators of Inflammation 2010: 20p.
  • Vykoukal D, Davies MG. Vascular Biology Of Metabolic Syndrome. J Vasc Surg 2011; 54: 819-31.
  • Zhong X, Zhang H, Tan H, Zhou Y, Liu F, Chen F, Shang D. Association Of Serum Omentin-1 Levels With Coronary Artery Disease. Acta Pharmacologica Sinica 2011; 32: 873–878.
  • Chu SH, Lee MK, Ahn KY, Im JA, Park MS, Lee DC, Jeon JY, Lee JW. Chemerin And Adiponectin Contribute Reciprocally To Metabolic Syndrome. PLoS One 2012; 7: e34710.
  • Romacho T, Sánchez-Ferrer CF, Peiró C. Visfatin/Nampt: An Adipokine With Cardiovascular Impact. Mediators of Inlammation 2013; 15p.
  • Adams JN, Cox AJ, Freedman BI, Langefeld CD, Carr JJ, Bowden DW. Genetic Analysis Of Haptoglobin Polymorphisms With Cardiovascular Disease And Type 2 Diabetes In The Diabetes Heart Study. Cardiovascular Diabetology 2013; 12:31.
  • Bao JP, Jiang LF, Chen WP, Hu PF, Wu LD. Expression Of Vaspin In The Joint And The Levels In The Serum And Synovial Fluid Of Patients With Osteoarthritis. Int J Clin Exp Med 2014; 7; (10): 3447-3453.
  • Cordido F, Garcia-Mayor RV, Larranaga A. Obesity, Adipose Tissue, Inflammation And Update On Obesity Management. Obes Control Ther 2014; 1; (2): 1-8.
  • Zabel BA, Zunigaa L, Ohyamaa T, Allenc SJ, Cichyd J, Handelc TM, Butchera EC. Chemoattractants, Extrecellular Proteases, And The Integrated Host Defense Response. Exp Hematol 2006; 34:1021–1032. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi / Gümüşhane University Journal of Health Sciences: 2015;4(3)
  • Aronis KN, Sahin-Efe A, Chamberland JP, Spiro A, Vokonas P, Mantzoros CS. Chemerin Levels As Predictor Of Acute Coronary Events: A Case–Control Study Nested Within The Veterans Affairs Normative Aging Study. Metabolism Clinical and Experimental 2014; 63: 760 – 766.
  • Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ. Chemerin, A Novel Adipokine That Regulates Adipogenesis And Adipocyte Metabolism. The Journal Of Biological Chemistry 2007; 282; 38: 28175–28188.
  • Barraco GM, Luciano R, Semeraro M, Prieto-Hontoria PL, Manco M. Recently Discovered Adipokines And Cardio-Metabolic Comorbidities In Childhood Obesity. Int J Mol Sci 2014; 15: 19760-19776.
  • Meder W, Wendland M, Busmann A, Kutzleb C, Spodsberg N, John H, Richter R, Schleuder R, Meyer M, Forssmann WG. Characterization Of Human Circulating Tıg2 As A Ligand For The Orphan Receptor. ChemR23. FEBS Letters 2003; 555: 495-499.
  • Wittamer V, Gre´goire F, Robberecht P, Vassart G, Communi D, Parmentier M. The CTerminal Nonapeptide Of Mature Chemerin Activates The Chemerin Receptor With Low Nanomolar Potency. The Journal of Biological Chemistry 2004; 279; (11): 9956– 9962.
  • MacDougald OA, Burant CF. The Rapidly Expanding Family Of Adipokines. Cell Metabolism 2007; 6: 159-161.
  • Zabel BA, Kwitniewski M, Banas M, Zabieglo K, Murzyn K, Cichy J. Chemerin Regulation And Role In Host Defense. Am J Clin Exp Immunol 2014; 3; (1):1-19.
  • Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin Is An Independent Marker Of The Metabolic Syndrome In A Caucasian Population – A Pilot Study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008; 152: 217–221.
  • Herová M, Schmid M, Gemperle C, Loretz C, Hersberger M. Low Dose Aspirin Is Associated With Plasma Chemerin Levels And May Reduce Adipose Tissue Inflammation. Atherosclerosis 2014; 235: 256-262.
  • Albadah MS, Dekhil H, Shaik SA, Alsaif MA, Shogair M, Nawaz S, Alfadda AA. Effect Of Weight Loss On Serum Osteocalcin And Its Association With Serum Adipokines. International Journal of Endocrinology 2015; 8 p. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi / Gümüşhane University Journal of Health Sciences: 2015;4(3)
  • Yoshimura T, Oppenheim JJ. Chemokine-like receptor 1 (CMKLR1) And Chemokine (C–C Motif) Receptor-Like 2 (Ccrl2); Two Multifunctional Receptors With Unusual Properties. Experimental Cell Research 2011; 317: 674 – 684.
  • Bondue B, Wittamer V, Parmentier M. Chemerin And Its Receptors In Leukocyte Trafficking, Inflammation And Metabolism. Cytokine&Growth Factor Reviews 2011; 22: 331–338.
  • Imai K, Takai K, Hanai T, Shiraki M, Suzuki Y, Hayashi H, Naiki T, Nishigaki Y, Tomita E, Shimizu M, Moriwaki H. Impact Of Serum Chemerin Levels On Liver Functional Reserves And Platelet Counts In Patients With Hepatocellular Carcinoma. Int J Mol Sci 2014; 15: 11294-11306.
  • Samson M, Edinger AL, Stordeur P, Rucker J, Verhasselt V, Sharron M, Govaerts C, Mollereau C, Vassart G, Doms RW, Parmentier M. ChemR23, A Putative Chemoattractant Receptor, Is Expressed In Monocyte-Derived Dendritic Cells And Macrophages And Is A Coreceptor For Sıv And Some Primary HIV-1 Strains. Eur J Immunol 1998; 28: 1689–1700.
  • Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D. Chemerin Is A Novel Adipokine Associated With Obesity And Metabolic Syndrome. Endocrinology 2007; 148: 4687–4694.
  • Fatima SS, Rehman R, Baig M, Khan TA. New Roles Of The Multidimensional Adipokine: Chemerin. Peptides 2014; 62: 15–20.
  • Cash JL, Norling LV, Perretti M. Resolution Of Inflammation: Targeting GPCRs That Interact With Lipids And Peptides. Drug Discovery Today 2014; 19: 1186-1192.
  • Conrad C, Mellera S, Gilliet M. Plasmacytoid Dendritic Cells In The Skin: To Sense Or Not To Sense Nucleic Acids. Seminars in Immunology 2009; 21: 101–109.
  • Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M, Sasaki S. Chemerin: A New Adipokine That Modulates Adipogenesis Via Its Own Receptor. Biochem Biophys Res Commun 2007; 362: 1013-8.
  • Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines And Insulin Resistance. Mol Med 2008; 14: 741-751.
  • Sell H, Laurencikiene J, Taube A, Eckardt K, Cramer A, Horrighs A, Arner P, Eckel J. Chemerin Is A Novel Adipocyte-Derived Factor Inducing Insulin Resistance In Primary Human Skeletal Muscle Cells. Diabetes 2009; 58: 2731-40. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi / Gümüşhane University Journal of Health Sciences: 2015;4(3)
  • Kłusek-Oksiuta M, Bialokoz-Kalinowska I, Tarasów E, Wojtkowska M, Werpachowska I, Lebensztejn DM. Chemerin As A Novel Non-Invasive Serum Marker Of Intrahepatic Lipid Content In Obese Children. Italian Journal of Pediatrics 2014; 40: 84.
  • Wang D, Yuan GY, Wang XZ, Jia J, Di LL, Yang L, Chen X, Qian FF, Chen JJ. Plasma Chemerin Level In Metabolic Syndrome. Genet Mol Res 2013; 12; (4): 5986-5991.

Chemerin

Yıl 2015, Cilt: 4 Sayı: 3, 468 - 481, 01.07.2015

Öz

Modern life style, food habits which changing technology in paralel and with each passing day more frequent exposured to stress conditions increases the risk of diseases such as high weight gain, insulin resistance, hypertension, Type 2 diabetes. Adipose tissue is an endocrine organ, which is responsible for the function of fat storage and,  also the synthesis and secretion of adipokines that is known the relation with many diseases. Chemerin is a protein, has been recently determined that a kind of adipokine and secreted by the adipose tissue and has the main function of chemoattractant and is associated with a lot of metabolic pathways including adipogenezis, angiogenesis and glucose homeostasis. Chemerin, is secreted by inactive forms from adipose tissue, may be turned to active functional forms with the removal of the carboxyl terminal amino acids by a variety of proteases. In a result, the people with inflammation, diabetes, metabolic syndrome, cardiovascular disease may have higher the level of chemerin comparing to the healthy people, in the future is suggest that may provide a new therapeutic approach for the diagnosis and control as predictors of these disease.
To aim of this review is shown that the structure and the function of chemerin, which has important regulator roles on different metabolic pathways and to explain the relation with diseases.

Kaynakça

  • Bays HE. Adiposopathy Is “Sick Fat” A Cardiovascular Disease? J Am Coll Cardiol 2011; 57: 2461–73.
  • Li Y, Shi B, Li S. Association Between Serum Chemerin Concentrations And Clinical Indices In Obesity Or Metabolic Syndrome: A Meta-Analysis. PLoS ONE 2014; 9; (12): e113915.
  • Altunkaynak BZB, Özbek E. Yağ Dokusu Endokrin Bir Organ Mıdır? Dicle Tıp Dergisi 2005; 32: 211-7.
  • Karastergiou K, Mohamed-Ali V. The Autocrine And Paracrine Roles Of Adipokines. Mol Cell Endocrinol 2010; 318: 69–78.
  • Rokling-Andersen MH, Reseland JE, Veierød MB, Anderssen SA, Jacobs Jr DR, Urdal P, Jansson JO, Drevon CA. Effects Of Long-Term Exercise And Diet Intervention On Plasma Adipokine Concentrations. Am J Clin Nutr 2007; 86: 1293–301.
  • Takeishi Y. Resistin Is A Novel Biomarker For A Risk Of Heart Failure. J Cardiovasc Dis Diagn 2013; 1:4.
  • AL-Suhaimi EA, Shehzad A. Leptin, Resistin And Visfatin: The Missing Link Between Endocrine Metabolic Disorders And Immunity. European Journal of Medical Research 2013; 18:12.
  • Crandall DL, Quinet EM, Morgan GA, Busler DE, Mchendry-Rinde B, Kral JG. Synthesis And Secretion Of Plasminogen Activator Inhibitor-1 By Human Preadipocytes. J Clin Endocrinol Metab 1999; 84: 3222–3227.
  • Berg AH, Scherer PE. Adipose Tissue, Inflammation, And Cardiovascular Disease. Circ Res 2005; 96: 939-949.
  • Alessi MC, Juhan-Vague I. PAI-1 And The Metabolic Syndrome Links, Causes, And Consequences. Arterioscler Thromb Vasc Biol 2006; 26: 2200-2207.
  • Ernst MC, Sinal CJ. Chemerin: At The Crossroads Of Inflammation And Obesity. Trends in Endocrinology and Metabolism 2010; 21:11.
  • Oberbach A, Kirscha K, Lehmanna S, Schlichting N, Fasshauer M, Zarse K, Stumvoll M, Ristow M, Blüher M, Kovacs P. Serum Vaspin Concentrations Are Decreased After Exercise-Induced Oxidative Stress. Obes Facts 2010; 3: 328–331.
  • Tiaka EK, Manolakis AC, Kapsoritakis AN, Potamianos SP. The Implication Of Adiponectin And Resistin In Gastrointestinal Diseases. Cytokine & Growth Factor Reviews 2011; 22: 109–119.
  • Bohler H, Mokshagundam S, Winters SJ. Adipose Tissue And Reproduction In Women. Fertil Steril 2010; 94: 795–825.
  • Fain JN. Release Of Inflammatorymediators By Human Adipose Tissue Is Enhanced In Obesity And Primarily By The Nonfat Cells: A Review. Mediators of Inflammation 2010: 20p.
  • Vykoukal D, Davies MG. Vascular Biology Of Metabolic Syndrome. J Vasc Surg 2011; 54: 819-31.
  • Zhong X, Zhang H, Tan H, Zhou Y, Liu F, Chen F, Shang D. Association Of Serum Omentin-1 Levels With Coronary Artery Disease. Acta Pharmacologica Sinica 2011; 32: 873–878.
  • Chu SH, Lee MK, Ahn KY, Im JA, Park MS, Lee DC, Jeon JY, Lee JW. Chemerin And Adiponectin Contribute Reciprocally To Metabolic Syndrome. PLoS One 2012; 7: e34710.
  • Romacho T, Sánchez-Ferrer CF, Peiró C. Visfatin/Nampt: An Adipokine With Cardiovascular Impact. Mediators of Inlammation 2013; 15p.
  • Adams JN, Cox AJ, Freedman BI, Langefeld CD, Carr JJ, Bowden DW. Genetic Analysis Of Haptoglobin Polymorphisms With Cardiovascular Disease And Type 2 Diabetes In The Diabetes Heart Study. Cardiovascular Diabetology 2013; 12:31.
  • Bao JP, Jiang LF, Chen WP, Hu PF, Wu LD. Expression Of Vaspin In The Joint And The Levels In The Serum And Synovial Fluid Of Patients With Osteoarthritis. Int J Clin Exp Med 2014; 7; (10): 3447-3453.
  • Cordido F, Garcia-Mayor RV, Larranaga A. Obesity, Adipose Tissue, Inflammation And Update On Obesity Management. Obes Control Ther 2014; 1; (2): 1-8.
  • Zabel BA, Zunigaa L, Ohyamaa T, Allenc SJ, Cichyd J, Handelc TM, Butchera EC. Chemoattractants, Extrecellular Proteases, And The Integrated Host Defense Response. Exp Hematol 2006; 34:1021–1032. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi / Gümüşhane University Journal of Health Sciences: 2015;4(3)
  • Aronis KN, Sahin-Efe A, Chamberland JP, Spiro A, Vokonas P, Mantzoros CS. Chemerin Levels As Predictor Of Acute Coronary Events: A Case–Control Study Nested Within The Veterans Affairs Normative Aging Study. Metabolism Clinical and Experimental 2014; 63: 760 – 766.
  • Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ. Chemerin, A Novel Adipokine That Regulates Adipogenesis And Adipocyte Metabolism. The Journal Of Biological Chemistry 2007; 282; 38: 28175–28188.
  • Barraco GM, Luciano R, Semeraro M, Prieto-Hontoria PL, Manco M. Recently Discovered Adipokines And Cardio-Metabolic Comorbidities In Childhood Obesity. Int J Mol Sci 2014; 15: 19760-19776.
  • Meder W, Wendland M, Busmann A, Kutzleb C, Spodsberg N, John H, Richter R, Schleuder R, Meyer M, Forssmann WG. Characterization Of Human Circulating Tıg2 As A Ligand For The Orphan Receptor. ChemR23. FEBS Letters 2003; 555: 495-499.
  • Wittamer V, Gre´goire F, Robberecht P, Vassart G, Communi D, Parmentier M. The CTerminal Nonapeptide Of Mature Chemerin Activates The Chemerin Receptor With Low Nanomolar Potency. The Journal of Biological Chemistry 2004; 279; (11): 9956– 9962.
  • MacDougald OA, Burant CF. The Rapidly Expanding Family Of Adipokines. Cell Metabolism 2007; 6: 159-161.
  • Zabel BA, Kwitniewski M, Banas M, Zabieglo K, Murzyn K, Cichy J. Chemerin Regulation And Role In Host Defense. Am J Clin Exp Immunol 2014; 3; (1):1-19.
  • Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin Is An Independent Marker Of The Metabolic Syndrome In A Caucasian Population – A Pilot Study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008; 152: 217–221.
  • Herová M, Schmid M, Gemperle C, Loretz C, Hersberger M. Low Dose Aspirin Is Associated With Plasma Chemerin Levels And May Reduce Adipose Tissue Inflammation. Atherosclerosis 2014; 235: 256-262.
  • Albadah MS, Dekhil H, Shaik SA, Alsaif MA, Shogair M, Nawaz S, Alfadda AA. Effect Of Weight Loss On Serum Osteocalcin And Its Association With Serum Adipokines. International Journal of Endocrinology 2015; 8 p. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi / Gümüşhane University Journal of Health Sciences: 2015;4(3)
  • Yoshimura T, Oppenheim JJ. Chemokine-like receptor 1 (CMKLR1) And Chemokine (C–C Motif) Receptor-Like 2 (Ccrl2); Two Multifunctional Receptors With Unusual Properties. Experimental Cell Research 2011; 317: 674 – 684.
  • Bondue B, Wittamer V, Parmentier M. Chemerin And Its Receptors In Leukocyte Trafficking, Inflammation And Metabolism. Cytokine&Growth Factor Reviews 2011; 22: 331–338.
  • Imai K, Takai K, Hanai T, Shiraki M, Suzuki Y, Hayashi H, Naiki T, Nishigaki Y, Tomita E, Shimizu M, Moriwaki H. Impact Of Serum Chemerin Levels On Liver Functional Reserves And Platelet Counts In Patients With Hepatocellular Carcinoma. Int J Mol Sci 2014; 15: 11294-11306.
  • Samson M, Edinger AL, Stordeur P, Rucker J, Verhasselt V, Sharron M, Govaerts C, Mollereau C, Vassart G, Doms RW, Parmentier M. ChemR23, A Putative Chemoattractant Receptor, Is Expressed In Monocyte-Derived Dendritic Cells And Macrophages And Is A Coreceptor For Sıv And Some Primary HIV-1 Strains. Eur J Immunol 1998; 28: 1689–1700.
  • Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D. Chemerin Is A Novel Adipokine Associated With Obesity And Metabolic Syndrome. Endocrinology 2007; 148: 4687–4694.
  • Fatima SS, Rehman R, Baig M, Khan TA. New Roles Of The Multidimensional Adipokine: Chemerin. Peptides 2014; 62: 15–20.
  • Cash JL, Norling LV, Perretti M. Resolution Of Inflammation: Targeting GPCRs That Interact With Lipids And Peptides. Drug Discovery Today 2014; 19: 1186-1192.
  • Conrad C, Mellera S, Gilliet M. Plasmacytoid Dendritic Cells In The Skin: To Sense Or Not To Sense Nucleic Acids. Seminars in Immunology 2009; 21: 101–109.
  • Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M, Sasaki S. Chemerin: A New Adipokine That Modulates Adipogenesis Via Its Own Receptor. Biochem Biophys Res Commun 2007; 362: 1013-8.
  • Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines And Insulin Resistance. Mol Med 2008; 14: 741-751.
  • Sell H, Laurencikiene J, Taube A, Eckardt K, Cramer A, Horrighs A, Arner P, Eckel J. Chemerin Is A Novel Adipocyte-Derived Factor Inducing Insulin Resistance In Primary Human Skeletal Muscle Cells. Diabetes 2009; 58: 2731-40. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi / Gümüşhane University Journal of Health Sciences: 2015;4(3)
  • Kłusek-Oksiuta M, Bialokoz-Kalinowska I, Tarasów E, Wojtkowska M, Werpachowska I, Lebensztejn DM. Chemerin As A Novel Non-Invasive Serum Marker Of Intrahepatic Lipid Content In Obese Children. Italian Journal of Pediatrics 2014; 40: 84.
  • Wang D, Yuan GY, Wang XZ, Jia J, Di LL, Yang L, Chen X, Qian FF, Chen JJ. Plasma Chemerin Level In Metabolic Syndrome. Genet Mol Res 2013; 12; (4): 5986-5991.
Toplam 46 adet kaynakça vardır.

Ayrıntılar

Diğer ID JA78PK47GE
Bölüm Makaleler
Yazarlar

Nurçin Küçük Kent Bu kişi benim

Yayımlanma Tarihi 1 Temmuz 2015
Yayımlandığı Sayı Yıl 2015 Cilt: 4 Sayı: 3

Kaynak Göster

APA Küçük Kent, N. (2015). Kemerin. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi, 4(3), 468-481.
AMA Küçük Kent N. Kemerin. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi. Temmuz 2015;4(3):468-481.
Chicago Küçük Kent, Nurçin. “Kemerin”. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi 4, sy. 3 (Temmuz 2015): 468-81.
EndNote Küçük Kent N (01 Temmuz 2015) Kemerin. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi 4 3 468–481.
IEEE N. Küçük Kent, “Kemerin”, Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi, c. 4, sy. 3, ss. 468–481, 2015.
ISNAD Küçük Kent, Nurçin. “Kemerin”. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi 4/3 (Temmuz 2015), 468-481.
JAMA Küçük Kent N. Kemerin. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi. 2015;4:468–481.
MLA Küçük Kent, Nurçin. “Kemerin”. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi, c. 4, sy. 3, 2015, ss. 468-81.
Vancouver Küçük Kent N. Kemerin. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi. 2015;4(3):468-81.